ReviewJournal of controlled release : official journal of the Controlled Release Society2013
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 315 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
315 citing papers in PubMed, 1 synthesis or guideline pooled it, 967 citations in OpenAlex.
- The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact.Current oncology reports · 2025Pooled it
- Restoring brain functions in the Mo-blo mouse model of Menkes disease with copper nanoclusters.Science advances · 2026Article
- Targeted Retention of Cationic Liposomes at the Inflamed Blood-Brain Barrier by Incorporating Mesenchymal Stem Cell Membrane.Advanced healthcare materials · 2026Article
- Harnessing synergistic SN38/quercetin nanomicelles via nebulized inhalation for enhanced lung cancer treatment.Drug delivery and translational research · 2026Article
- Plant-derived CTLA-4-targeting miR152 via lipid nanoparticles potentiates doxorubicin efficacy in breast cancer immunochemotherapy.Science China. Life sciences · 2026Article
- Solvent-free Nanoparticle Assembly Protocol (SNAP): one-pot formulation of drug loaded polyester nanoparticles and their vessel size-dependent perivascular transport in the brain.bioRxiv : the preprint server for biology · 2026Article
- Investigating theBioconjugate chemistry · 2026Article
- Liposome Particle Size Prediction by In-Line Process Analytical Technology (PAT)-Integrated Machine Learning.Small methods · 2026Article
- Nanozymes for Advanced Hemoglobin-Based Oxygen Carriers: Applications in Blood Substitution, Wound Healing, Antitumor Therapy, and Beyond.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- NanoformulatedNanomaterials (Basel, Switzerland) · 2026Article
- In vivo toxicity assessment of silica-coated iron oxide nanoparticles for nanowarming in organ cryopreservation.Journal of nanobiotechnology · 2026Article
- Photothermal activity in cancer therapy and antimicrobial properties of green gold nanoparticles from winery waste.RSC advances · 2026Article
- Formulation-Dependent Antibacterial Performance: Design and Biomedical Applications.Gels (Basel, Switzerland) · 2026Review
- Core-shell nanotherapeutics for diabetic cataract and retinopathy: current state-of-the-art and translational challenges.Drug delivery and translational research · 2026Review
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Inhalable perfluorocarbon RNA nanocapsules overcome biological barriers to treat lung metastases.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Tumor radiosensitization with gold nanoparticles: evolving strategies to improve tumoral gold uptake and catalyze future clinical translation.ACS nano medicine · 2026Article
- Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization.BMC cancer · 2026Article
- Intravital microscopy for nanomedicine: investigating nanoparticle-tissue interactions in the native state.RSC advances · 2026Review
- Nanozyme-Driven Ferroptosis-Cuproptosis Interplay in Lung Cancer.International journal of nanomedicine · 2026Review
255 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Nanoparticle drug delivery to the tumor is impacted by multiple factors: nanoparticles must evade clearance by renal filtration and the reticuloendothelial system, extravasate through the enlarged endothelial gaps in tumors, penetrate through dense stroma in the tumor microenvironment to reach the tumor cells, remain in the tumor tissue for a prolonged period of time, and finally release the active agent to induce pharmacological effect. The physicochemical properties of nanoparticles such as size, shape, surface charge, surface chemistry (PEGylation, ligand conjugation) and composition affect the pharmacokinetics, biodistribution, intratumoral penetration and tumor bioavailability. On the other hand, tumor biology (blood flow, perfusion, permeability, interstitial fluid pressure and stroma content) and patient characteristics (age, gender, tumor type, tumor location, body composition and prior treatments) also have impact on drug delivery by nanoparticles. It is now believed that both nanoparticles and the tumor microenvironment have to be optimized or adjusted for optimal delivery. This review provides a comprehensive summary of how these nanoparticle and biological factors impact nanoparticle delivery to tumors, with discussion on how the tumor microenvironment can be adjusted and how patients can be stratified by imaging methods to receive the maximal benefit of nanomedicine. Perspectives and future directions are also provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.